rituximab + cyclophosphamide + doxorubicin + vincristine + etoposide + prednisone + methotrexate + cytarabine

This is a multi-agent lymphoma regimen that combines the anti-CD20 monoclonal antibody rituximab with the cytotoxic agents cyclophosphamide, doxorubicin, vincristine, etoposide, and the corticosteroid prednisone, plus central nervous system–directed antimetabolites methotrexate and cytarabine. Core R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) is an established combination for aggressive B‑cell lymphomas, often given as dose-adjusted continuous infusions; methotrexate and cytarabine are added for CNS prophylaxis or treatment in high‑risk settings such as Burkitt lymphoma or diffuse large B‑cell lymphoma with high CNS relapse risk, typically administered intrathecally or as systemic high‑dose methotrexate depending on protocol.[1][2][5][8]

Other names

R-EPOCH plus CNS-directed methotrexate and cytarabineDA-EPOCH-R with intrathecal methotrexate and cytarabineEPOCH-R with CNS prophylaxis